Parkinson’s Disease Market Analysis and Forecasts to 2022

Parkinson’s Disease Market Size, Share, Trends, Company Profiles, Demand,

Insights, Analysis, Research, Report, Opportunities, Segmentation and

Forecast To 2022

Parkinson’s disease (PD) is the second common neurodegenerative disease after Alzheimer’s. It

usually affects people above the age of 50 with symptoms of bradykinesia and rigidity being the

most common. It is caused by the loss of dopamine-producing neurons within the basal ganglia.

As the disease progresses, it leads to disability in patients restricting major motor functions.

PD is difficult to diagnose without a medical history or neurological examination. Patients in the

advanced stages suffer from shaking and difficulty of swallowing and chewing. Other symptoms

include depression, impaired balance, and urinary problems. Anticholinergics can control the

tremors mixed with levodopa. Carbidopa delays the conversion of levodopa before it changes to

dopamine. Other dopamine agonists include pramipexole, ropinirole, and bromocriptine mimic

the same role as dopamine.

The market currently offers drugs which offer symptomatic relief. The global geriatric

population is the major driver of Parkinson’s disease drug market. But the need for a diseasemodifying drug will drive the market demand over the years ahead. The market is projected to

reach about USD 5 billion by 2022.

For further information on this report, please visit http://www.radiantinsights.com/research/frontier-pharma-parkinsons-disease

Levodopa is the current reigning drug in the market among other dopamine agonists and

Monoamine Oxidase B (MAO-B). Germany, Spain, Japan, Italy, United States, United Kingdom,

and France are major sales regions for the market. Despite new drug therapies and

dopaminenergic drugs, the market is at risk of being offset by generic competition. Launch of

Xadago and Rytary are expected to improve drug sales for the market till 2022. Other drugs in

the pipeline include Intec’s CD/LD-GR, Bial’s opicapone, Biotie’s tozadenant,...